successfully infused CAR-T cells targeting epidermal growth factor receptor (EGFR) and CD133 into a patient with metastatic CCA and achieved small increases in overall survival and cancer cell death, especially when combined with other therapies (95). This evidence concerns the gene PROM1 and cancer.